Johnson Health Tech, Co Ltd. is a global leader in commercial and residential fitness equipment manufacturing. Headquartered in Taiwan with a North American presence in Cottage Grove, Wisconsin, the company’s brand family includes some of the most respected names in the fitness and wellness industry, including Matrix®, Vision®, BowFlex®, Schwinn®, Horizon®, JRNY®, Fujiiryoki, and Johnson Fitness & Wellness. The company’s products are available commercially and sold direct to consumer on brand websites, through retail partners, and in more than 460 Johnson Fitness & Wellness retail locations worldwide.

Agiliti is a leading manufacturer and service provider of essential medical and surgical equipment to the U.S. healthcare industry. Agiliti serves more than 10,000 national, regional and local acute care and alternate site providers across the U.S. For more than eight decades, Agiliti has delivered medical device management and service solutions that help healthcare providers reduce costs, increase operating efficiencies and support optimal patient outcomes.

Demant A/S is an international hearing health care company within hearing aids, audiometric equipment, and personal communication.

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. The Company’s lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Additional pipeline programs span across multiple inner ear disorders, and include CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision; GJB2 for a common form of monogenic deafness and hearing loss; and delivery of an anti-VEGF, an inhibitor of vascular endothelial growth factor, or VEGF, a protein that can cause abnormal blood vessel growth, for the treatment of vestibular schwannoma, a tumor of the auditory vestibular nerve.